Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse.

Abstract:

BACKGROUND:Inflammatory bowel diseases (IBD) are characterized by intermittent relapses, and their course is heterogeneous and unpredictable. Our aim was to determine the ability of protein, metabolite, or microbial biomarkers to predict relapse in patients with quiescent disease. METHODS:This prospective study enrolled patients with quiescent Crohn disease and ulcerative colitis, defined as the absence of clinical symptoms (Harvey-Bradshaw Index ≤ 4, Simple Clinical Colitis Activity Index ≤ 2) and endoscopic remission within the prior year. The primary outcome was relapse within 2 years, defined as symptomatic worsening accompanied by elevated inflammatory markers resulting in a change in therapy or IBD-related hospitalization or surgery. Biomarkers were tested in a derivation cohort, and their performance was examined in an independent validation cohort. RESULTS:Our prospective cohort study included 164 patients with IBD (108 with Crohn disease, 56 with ulcerative colitis). Upon follow-up for a median of 1 year, 22 patients (13.4%) experienced a relapse. Three protein biomarkers (interleukin-10, glial cell line-derived neurotrophic factor, and T-cell surface glycoprotein CD8 alpha chain) and 4 metabolomic markers (propionyl-L-carnitine, carnitine, sarcosine, and sorbitol) were associated with relapse in multivariable models. Proteomic and metabolomic risk scores independently predicted relapse with a combined area under the curve of 0.83. A high proteomic risk score (odds ratio = 9.11; 95% confidence interval, 1.90-43.61) or metabolomic risk score (odds ratio = 5.79; 95% confidence interval, 1.24-27.11) independently predicted a higher risk of relapse over 2 years. Fecal metagenomics showed an increased abundance of Proteobacteria (P = 0.0019, q = 0.019) and Fusobacteria (P = 0.0040, q = 0.020) and at the species level Lachnospiraceae_bacterium_2_1_58FAA (P = 0.000008, q = 0.0009) among the relapses. CONCLUSIONS:Proteomic, metabolomic, and microbial biomarkers identify a proinflammatory state in quiescent IBD that predisposes to clinical relapse.

journal_name

Inflamm Bowel Dis

authors

Borren NZ,Plichta D,Joshi AD,Bonilla G,Sadreyev R,Vlamakis H,Xavier RJ,Ananthakrishnan AN

doi

10.1093/ibd/izaa183

subject

Has Abstract

pub_date

2020-09-18 00:00:00

pages

1524-1532

issue

10

eissn

1078-0998

issn

1536-4844

pii

5885066

journal_volume

26

pub_type

杂志文章
  • Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial.

    abstract:BACKGROUND:Extracorporeal photopheresis (ECP) involves ex vivo leukocyte treatment with methoxsalen and UVA light to generate a tolerogenic response. A previous trial demonstrated that ECP permits corticosteroid withdrawal in steroid-dependent Crohn's disease (CD) patients who were in clinical remission. We studied the...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/ibd.23012

    authors: Reinisch W,Knobler R,Rutgeerts PJ,Ochsenkühn T,Anderson F,von Tirpitz C,Kaatz M,Janneke van der Woude C,Parenti D,Mannon PJ

    更新日期:2013-02-01 00:00:00

  • Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease.

    abstract::Chemokines, a large family of small chemoattractive cytokines, and their receptors play an integral role in the regulation of the immune response and homeostasis. The ability of chemokines to attract specific populations of immune cells sets them apart from other chemoattractants. Chemokines produced within the gastro...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20480

    authors: Zimmerman NP,Vongsa RA,Wendt MK,Dwinell MB

    更新日期:2008-07-01 00:00:00

  • Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease.

    abstract::The conventional treatment of inflammatory bowel disease (IBD) has focused on nonspecifically targeting mucosal inflammation. In the last decade, with the advent of novel biological agents that directly inhibit proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), rapid progress has been made in clin...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21336

    authors: Coffin CS,Fraser HF,Panaccione R,Ghosh S

    更新日期:2011-01-01 00:00:00

  • Words fail me: the verbal IQ deficit in inflammatory bowel disease and irritable bowel syndrome.

    abstract:BACKGROUND:Many chronic illnesses are accompanied by impaired cognitive functioning. In people with Inflammatory Bowel Disease (IBD), there is some research to suggest a decrement in verbal IQ (VIQ), when compared to people with Irritable Bowel Syndrome (IBS) and healthy controls. Although this is an important finding,...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20837

    authors: Dancey CP,Attree EA,Stuart G,Wilson C,Sonnet A

    更新日期:2009-06-01 00:00:00

  • Human β-defensin 3 peptide is increased and redistributed in Crohn's ileitis.

    abstract:BACKGROUND:Antimicrobial peptides (AMPs) maintain a sterile environment in intestinal crypts, limiting microbial colonization and invasion. Decreased AMP expression is proposed to increase the risk for inflammatory bowel disease. Expression and function of inducible AMPs, human β-defensin 2 and 3 (hBD-2 and hBD-3), rem...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318280b11a

    authors: Meisch JP,Nishimura M,Vogel RM,Sung HC,Bednarchik BA,Ghosh SK,Fu P,McCormick T,Weinberg A,Levine AD

    更新日期:2013-04-01 00:00:00

  • Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study.

    abstract:BACKGROUND:A subset of patients with ulcerative colitis (UC) will require colectomy within a few years of diagnosis. Thus, our aim was to determine the clinical predictors of early colectomy among patients with UC who are hospitalized with an acute flare. METHODS:Using population-based surveillance (1996-2009), all ad...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001211

    authors: Al-Darmaki A,Hubbard J,Seow CH,Leung Y,Novak K,Shaheen AA,Panaccione R,Kaplan GG

    更新日期:2017-08-01 00:00:00

  • Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

    abstract::Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000444

    authors: Viennois E,Zhao Y,Merlin D

    更新日期:2015-10-01 00:00:00

  • Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis.

    abstract:BACKGROUND:Improved treatment approaches for ulcerative colitis (UC), including novel medications, might reduce the need for colectomy. We performed a retrospective cohort study of adult patients (age 18-64) with UC in the United States to examine time trends for colectomy and biologic use from 2007 to 2016. METHODS:W...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz247

    authors: Barnes EL,Jiang Y,Kappelman MD,Long MD,Sandler RS,Kinlaw AC,Herfarth HH

    更新日期:2020-07-17 00:00:00

  • Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts.

    abstract:BACKGROUND:We performed a worldwide survey to evaluate the extent to which gastroenterologists who are experts in the field of inflammatory bowel diseases (IBDs) are utilizing thiopurine metabolism in practice. METHODS:This was a Web-based cross-sectional survey consisting of 12 multiple-choice and open-ended question...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21662

    authors: Roblin X,Oussalah A,Chevaux JB,Sparrow M,Peyrin-Biroulet L

    更新日期:2011-12-01 00:00:00

  • Clinical epidemiology of inflammatory bowel disease in Lebanon.

    abstract:BACKGROUND:The objectives of this study were to determine the prevalence and incidence of inflammatory bowel disease (IBD) in a representative Lebanese cohort and to describe practice prevalence trends, disease characteristics, and impact on quality of life (QoL) of IBD patients in Lebanon. METHODS:All of a university...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20022

    authors: Abdul-Baki H,ElHajj I,El-Zahabi LM,Azar C,Aoun E,Zantout H,Nasreddine W,Ayyach B,Mourad FH,Soweid A,Barada KA,Sharara AI

    更新日期:2007-04-01 00:00:00

  • Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis.

    abstract:BACKGROUND:The role of antiviral therapy in patients with ulcerative colitis (UC) with cytomegalovirus (CMV) remains unclear. We therefore performed a systematic review and meta-analysis to assess the association between antiviral therapy and the risk of colectomy. METHODS:Multiple electronic databases were searched s...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/MIB.0000000000000489

    authors: Shukla T,Singh S,Loftus EV Jr,Bruining DH,McCurdy JD

    更新日期:2015-11-01 00:00:00

  • Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.

    abstract:BACKGROUND:Mesalamine, 5-aminosalicylic acid (5-ASA), is a potent antioxidant and is known to enhance peroxisome proliferator-activated receptor γ activity in the intestine. Our previous studies suggested reduced Phosphoinositide 3-Kinase (PI3K)/β-catenin signaling as a mechanism for 5-ASA chemoprevention in chronic ul...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318297d741

    authors: Managlia E,Katzman RB,Brown JB,Barrett TA

    更新日期:2013-09-01 00:00:00

  • Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis.

    abstract:BACKGROUND:Oral ferrous iron therapy may reinforce intestinal inflammation. One possible mechanism is by catalyzing the production of reactive oxygen species. We studied the effects of low-dose oral ferrous fumarate on intestinal inflammation and plasma redox status in dextran sulfate sodium (DSS)-induced colitis in ra...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000174374.83601.86

    authors: Erichsen K,Milde AM,Arslan G,Helgeland L,Gudbrandsen OA,Ulvik RJ,Berge RK,Hausken T,Berstad A

    更新日期:2005-08-01 00:00:00

  • Crohn's disease runs a more aggressive course in young Asian patients.

    abstract:BACKGROUND:Crohn's disease is a heterogeneous inflammatory bowel disease. The impact of age at diagnosis on the clinical course of patients varies widely as reported in the Western literature. Using the Vienna Classification, we seek to determine whether young Crohn's disease patients in an Asian population followed a ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000195390.11645.7d

    authors: Thia KT,Luman W,Jin OC

    更新日期:2006-01-01 00:00:00

  • Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis.

    abstract:BACKGROUND:Intestinal stenosis is a frequent complication of Crohn's disease, often leading to repeated bowel obstruction and surgery. The prevalence of small bowel stenosis has ranged from 20% to 40% and from 7% to 15% in patients with colonic disease. Although balloon dilation is the initial preferred approach, many ...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,评审

    doi:10.1002/ibd.20318

    authors: Swaminath A,Lichtiger S

    更新日期:2008-02-01 00:00:00

  • The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease.

    abstract::Anorexia, malnutrition, altered body composition and development of mesenteric obesity are well known features of inflammatory bowel disease (IBD). Recent data suggest that dysregulation of protein secretion by white adipose tissue is involved in these manifestations of patients with IBD. Adipocytes are recently recog...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/01.mib.0000178915.54264.8f

    authors: Karmiris K,Koutroubakis IE,Kouroumalis EA

    更新日期:2005-09-01 00:00:00

  • Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis.

    abstract:BACKGROUND:The pathophysiological basis for corticosteroid (CS) failure in ulcerative colitis (UC) is unknown. A transactivation glucocorticoid bioassay (GBA) was developed to measure the biological activity of CS by quantifying glucocorticoid response elements. This approach eliminates differences in bioavailability, ...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/ibd.21070

    authors: Turner D,Kolho KL,Mack DR,Raivio T,Leleiko N,Crandall W,Markowitz J,Silverberg MS,Jänne OA,Stempak J,Hyams J,Griffiths AM

    更新日期:2010-03-01 00:00:00

  • Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD.

    abstract::Crohn's disease and ulcerative colitis are quite often complicated with manifestations in extraintestinal organs like joints, eye, and skin. Although the etiopathogenesis of these nonmucosal complications remains unsettled, they all share the characteristic feature of inappropriate leukocyte recruitment in nonlymphati...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.3780040210

    authors: Salmi M,Jalkanen S

    更新日期:1998-05-01 00:00:00

  • Dipeptidyl peptidase expression during experimental colitis in mice.

    abstract:BACKGROUND:We have previously demonstrated that inhibition of dipeptidyl peptidase (DP) activity partially attenuates dextran sulfate sodium (DSS) colitis in mice. The aim of this study was to further investigate the mechanisms of this protection. MATERIALS AND METHODS:Wildtype (WT) and DPIV(-/-) mice consumed 2% DSS ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21241

    authors: Yazbeck R,Sulda ML,Howarth GS,Bleich A,Raber K,von Hörsten S,Holst JJ,Abbott CA

    更新日期:2010-08-01 00:00:00

  • Muc5ac Expression Protects the Colonic Barrier in Experimental Colitis.

    abstract:BACKGROUND:The mucus gel layer (MGL) lining the colon is integral to exclusion of bacteria and maintaining intestinal homeostasis in health and disease. Some MGL defects allowing bacteria to directly contact the colonic surface are commonly observed in ulcerative colitis (UC). The major macromolecular component of the ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa064

    authors: Olli KE,Rapp C,O'Connell L,Collins CB,McNamee EN,Jensen O,Jedlicka P,Allison KC,Goldberg MS,Gerich ME,Frank DN,Ir D,Robertson CE,Evans CM,Aherne CM

    更新日期:2020-08-20 00:00:00

  • Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.

    abstract:BACKGROUND:Histamine is a key immunoregulatory mediator in immediate-type hypersensitivity reactions and chronic inflammatory responses, in particular histamine suppresses proinflammatory responses to bacterial ligands, through histamine receptor 2 (H2R). The aim of this study was to investigate the effects of histamin...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000825

    authors: Smolinska S,Groeger D,Perez NR,Schiavi E,Ferstl R,Frei R,Konieczna P,Akdis CA,Jutel M,OʼMahony L

    更新日期:2016-07-01 00:00:00

  • Site organization and management.

    abstract::The principal investigator is responsible for everything involved in the conduct of a clinical research study. Prior to the initiation of any clinical trial, an investigator must become acquainted with the material requirements, personnel needs, and best practices involved in the conduct of the trial. Commitment to a ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000184848.61687.52

    authors: Wolf DC,Katz S,Safdi MA,Sandler RS,Lewis JD

    更新日期:2005-11-01 00:00:00

  • Adalimumab therapy in Crohn's disease of the ileal pouch.

    abstract:BACKGROUND:Crohn's disease (CD) of the pouch can develop in patients with ileal pouch-anal anastomosis, resulting in significant morbidities, even pouch failure. The aim of this study was to evaluate short- and long-term outcome of adalimumab (ADA) in treating these patients. METHODS:A total of 48 patients who receive...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1002/ibd.22933

    authors: Li Y,Lopez R,Queener E,Shen B

    更新日期:2012-12-01 00:00:00

  • Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

    abstract:BACKGROUND AND AIMS:Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200608000-00011

    authors: Fakhoury M,Lecordier J,Medard Y,Peuchmaur M,Jacqz-Agrain E

    更新日期:2006-08-01 00:00:00

  • Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach.

    abstract:BACKGROUND:Disappearance of macroscopic mucosal inflammation predicts long-term outcome in Crohn's disease (CD). It can be assessed by ileocolonoscopy, which is, however, an invasive and expensive procedure. Disease activity indices do not correlate well with endoscopic activity and noninvasive markers have a low sensi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000436

    authors: Bodelier AG,Smolinska A,Baranska A,Dallinga JW,Mujagic Z,Vanhees K,van den Heuvel T,Masclee AA,Jonkers D,Pierik MJ,van Schooten FJ

    更新日期:2015-08-01 00:00:00

  • Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease.

    abstract:BACKGROUND:Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort. METHODS:Inflammatory bowel disease pa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa014

    authors: Carney H,Marrie RA,Bolton JM,Patten SB,Graff LA,Bernstein CN,Kowalec K

    更新日期:2021-01-01 00:00:00

  • Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.

    abstract::Crohn's disease is an idiopathic, chronic inflammatory disorder of the digestive tract with heterogeneous clinical presentations. Crohn's is currently not a curable disease, and patients are faced with a lifetime of recurrent disease flare-ups and remissions. Management strategies for Crohn's must therefore be targete...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/00054725-200407002-00002

    authors: Lichtenstein GR,Hanauer SB,Kane SV,Present DH

    更新日期:2004-07-01 00:00:00

  • Sarcopenia and Inflammatory Bowel Disease: A Systematic Review.

    abstract:Background:Sarcopenia is associated with increased morbidity and mortality in oncologic and transplant surgery. It has a high incidence in chronic inflammatory states including inflammatory bowel disease (IBD). The validity of existing data in IBD and of sarcopenia's correlation with surgical outcomes is limited. Meth...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy212

    authors: Ryan E,McNicholas D,Creavin B,Kelly ME,Walsh T,Beddy D

    更新日期:2019-01-01 00:00:00

  • Hospital Admissions, Biological Therapy, and Surgery in Familial and Sporadic Cases of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011.

    abstract:BACKGROUND:Easily accessible predictors of disease course in inflammatory bowel disease (IBD) are scarce, and it remains largely unknown whether a family history of IBD predicts the course of Crohn's disease (CD) and ulcerative colitis (UC). We aimed to compare the course of disease in familial and sporadic cases of IB...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000545

    authors: Trier Moller F,Andersen V,Andersson M,Jess T

    更新日期:2015-12-01 00:00:00

  • A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease-Entering an Era of Regenerative Medicine.

    abstract::Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation....

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1093/ibd/izy084

    authors: Lightner AL

    更新日期:2018-07-12 00:00:00